Scholar Rock Holding Corporation
SRRKHealthcareNASDAQBiotechnology · Last scanned Jun 3, 2026
Scan Results
Daily timeframeScholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating. Valued at $5.35B, SRRK is a mid-cap name in its sector. The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform.
Market Cap
$5.35B
Beta
0.71
P/E (TTM)
—
P/E (Fwd)
-18.58
EPS (TTM)
$-3.45
EPS (Fwd)
$-2.41
ROE
-138.9%
ROA
-54.3%
Cash
$479.9M
Total Debt
$205.7M
Free CF
-$171.9M
52W Change
45.0%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $479.9M in cash comfortably exceeding the $205.7M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$171.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -138.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $18.8M (2021) to $0 (2025), a 100% decline worth watching.
With cash comfortably exceeding debt, SRRK has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing SRRK's risk profile alongside its fundamentals and technical indicators provides a more complete picture.